Readystate Asset Management LP Has $1.52 Million Position in Janux Therapeutics, Inc. $JANX

Readystate Asset Management LP cut its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 87.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 109,425 shares of the company’s stock after selling 776,470 shares during the quarter. Readystate Asset Management LP’s holdings in Janux Therapeutics were worth $1,521,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in JANX. Rock Springs Capital Management LP increased its position in shares of Janux Therapeutics by 2.3% during the 1st quarter. Rock Springs Capital Management LP now owns 367,009 shares of the company’s stock worth $5,101,000 after purchasing an additional 8,211 shares in the last quarter. Quantinno Capital Management LP lifted its holdings in Janux Therapeutics by 7.6% during the 1st quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock valued at $362,000 after purchasing an additional 1,846 shares during the last quarter. Rangeley Capital LLC boosted its position in Janux Therapeutics by 382.0% in the first quarter. Rangeley Capital LLC now owns 122,500 shares of the company’s stock valued at $1,703,000 after buying an additional 97,086 shares in the last quarter. Weiss Asset Management LP acquired a new position in Janux Therapeutics in the first quarter valued at about $1,295,000. Finally, BML Capital Management LLC bought a new stake in Janux Therapeutics during the first quarter worth about $2,154,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 3.7%

Shares of NASDAQ JANX opened at $15.00 on Wednesday. Janux Therapeutics, Inc. has a 1-year low of $12.12 and a 1-year high of $35.34. The company has a market cap of $914.70 million, a PE ratio of -8.15 and a beta of 2.52. The company has a 50-day moving average of $14.86 and a two-hundred day moving average of $14.35.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.13. The company had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.36 million. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on JANX shares. JonesTrading dropped their price objective on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, April 28th. Piper Sandler decreased their price target on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Monday, July 20th. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Finally, Evercore set a $22.00 price objective on Janux Therapeutics in a research note on Monday, May 11th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $38.08.

Insider Buying and Selling at Janux Therapeutics

In other news, VP Maria Dobek sold 2,038 shares of Janux Therapeutics stock in a transaction on Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the completion of the sale, the vice president directly owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. This trade represents a 5.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Janeen Noel Doyle sold 4,059 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the sale, the insider owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is currently owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.